Evidence map›Paper›PMID 40764322›Full record

ArticleScientific reports2025

Phage-mediated TLR2 signaling attenuates intracellular Mycobacterium abscessus survival in macrophages.

Hannah Kapoor, Aaron M Maves, Madeline A Bowder, Lia Danelishvili

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Phage therapy againstFrontiers in microbiology · 2026
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hannah Kapoor *Department of Biochemistry and Molecular Biology, College of Science, Oregon State University, Corvallis, OR, USA.
Aaron M Maves *Department of Microbiology, College of Science, Oregon State University, Corvallis, OR, USA.
Madeline A BowderDepartment of Biochemistry and Molecular Biology, College of Science, Oregon State University, Corvallis, OR, USA.
Lia DanelishviliDepartment of Microbiology, College of Science, Oregon State University, Corvallis, OR, USA. lia.danelishvili@oregonstate.edu.

Funding

Good Samaritan Hospital Foundation, the John C. Erkkila, M.D. Endowment for Health and Human Performance F1237BThe OSU Biomedical Department Research Grant VMDGDR-VG78
6 · The paper itself

Abstract

The incidence of pulmonary infections caused by M. abscessus (MAB) is on rise globally. Despite susceptible infections, long-term, and combinational treatment, patients respond to MAB therapy only partially with low success rates. In recent years, therapeutic phages have been used in combination with antibiotics to enhance treatments for patients suffering with drug-resistant, chronic, and disseminated mycobacterial infections with favorable clinical outcomes. While phages are commonly recognized for their antimicrobial role through direct lysis of bacteria, expanding body of literature, describing phage interactions with the immune system, indicates that the therapeutic impact of phage may not solely hinge on lytic activity but also on stimulating innate immune responses. In this study, we aimed to uncover phages that work synergistically with macrophage cellular mechanisms, enhancing phagocyte-mediated reduction of intracellular MAB. We discovered phages stimulating TLR2 signaling associated with NLRP3 inflammasome activation, resulting in substantial attenuation of the intracellular pathogen growth. We also uncovered a new phenomenon of intracellular elimination of MAB through fusion of lytic phage vacuoles with bacterial phagosomes. This process is driven by a cellular mechanism triggered by phage exposure to phagocytic cells. New therapeutic characteristics of phage, described in this study, will contribute to future phage-based therapeutic interventions.

Indexed as

BacteriophagesMacrophagesMycobacterium abscessusMycobacterium Infections, NontuberculousSignal TransductionToll-Like Receptor 2AnimalsHumansInflammasomesMiceMicrobial ViabilityNLR Family, Pyrin Domain-Containing 3 ProteinPhagocytosisPhagosomesInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinTLR2 protein, humanToll-Like Receptor 2Caspase 1Innate immunityInterleukin 1β (IL-1β)Mycobacterium abscessusNLRP3 inflammasomePhage therapyTHP-1 macrophagesToll-like receptor 2 (TLR2)

Identifiers

PMID40764322
PMCPMC12325590

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.